Birch Oil and Sore Muscles: What the Evidence Shows

A 2014 Cochrane review concluded that "the evidence does not support the use of topical rubefacients containing salicylates for acute injuries or chronic conditions" (Derry et al., 2014). The trials behind that conclusion tested finished products, not essential oil, and nothing in them can be carried over to a bottle of birch oil. This is a neutral report on what is published about methyl salicylate rub products. We do not make a sore-muscle argument for our oil, and nothing below should be read as one.

Birch Essential Oil bottle

Birch Essential Oil

Our own Birch Essential Oil, in sizes from 1 oz to bulk.

From $15.99

Shop Now →

What the two big reviews found, and how the estimate shrank

The earlier review is the optimistic one. A 2004 BMJ analysis pooled three double-blind placebo-controlled trials in acute pain (182 patients) and reported a number needed to benefit (NNT) of 2.1; for chronic pain, six trials (429 patients) gave an NNT of 5.3, "but larger, more valid studies were without significant effect." The authors also wrote that efficacy estimates were "unreliable owing to a lack of good clinical trials" (Mason et al., 2004).

The 2014 Cochrane update added data and got a weaker result. For acute pain, 6 placebo-controlled studies (560 participants) gave a risk ratio of 1.9 and an NNT of 3.2 at seven days, "but this result was not robust (very low quality evidence)." For chronic pain, 7 placebo-controlled studies (489 participants) gave a risk ratio of 1.6 and an NNT of 6.2, also rated very low quality. The authors added that any evidence of efficacy came from the older, smaller studies, while the larger, more recent ones reported no effect (Derry et al., 2014). In plain terms, the acute NNT worsened from 2.1 to 3.2 and the chronic one from 5.3 to 6.2 as better trials arrived.

One more limit matters for anyone reading these numbers: the salicylates in the trials were "different salicylates combined with various other potentially active ingredients." The reviews are about a product class, not methyl salicylate alone, and not oil.

What each document is, and what it can and cannot tell you
SourceTypeMain findingQuality as stated by the authors
Cochrane review, 2014Systematic reviewAcute NNT 3.2, chronic NNT 6.2 versus placeboVery low quality; larger recent trials showed no effect
BMJ review, 2004Systematic reviewAcute NNT 2.1, chronic NNT 5.3Estimates unreliable for lack of good trials
FDA OTC monograph M017, 2023Regulatory orderMethyl salicylate allowed at 10-60% as a counterirritantA rule on concentrations and labels, not trial data
FDA safety communication, 2012Adverse-event review43 burn cases with menthol and methyl salicylate productsCase series, no rate of occurrence
Morra et al., 199612 volunteers, 12.5% ointmentAbsorption rose with repeated applicationSmall pharmacokinetic study
Danon et al., 19866 volunteersMore than 3 times the absorption with exercise in heatSmall pharmacokinetic study

What the regulated products contain, and why the oil is a different object

FDA's external analgesic monograph (M017, section M017.12) permits methyl salicylate at 10 to 60% as a "counterirritant," defined as a topical drug that "causes irritation or mild inflammation of the skin for the purpose of relieving pain in muscles, joints, or viscera distal to the site of application" (FDA, 2023). The monograph is the source of the 10-60% range that circulates online; it is not in 21 CFR part 348, which now covers only male genital desensitizers.

Authentic sweet birch oil is 93.24-99.84% methyl salicylate (Dosoky et al., 2022). By arithmetic, undiluted oil sits above the 60% ceiling of the monograph, so neither the trial concentrations nor the monograph range describe a bottle of birch oil. A drug-labeled product must also carry specific warnings: "For external use only," "Do not apply to wounds or damaged skin," and "Do not bandage tightly" (FDA, 2023). FDA's salicylate labeling rule adds that a drug containing more than 5% methyl salicylate "should bear a conspicuous warning such as: 'Do not use otherwise than as directed'" (21 CFR 201.314).

There is also the question of intent. FDA states that a product's regulatory status "depends mainly on how [it is] intended to be used," judged from labeling, websites and advertising, and that claims such as easing pain or relaxing muscles are drug claims (FDA, aromatherapy page). This is the reason our site does not present birch oil as a muscle product. Our Inside the Still page says we are deliberately not making that argument, and the regulatory framework above is a practical reason to keep it that way.

The safety record that comes with these products

The same products have a documented injury pattern. In 2012 FDA reported rare cases of first- to third-degree chemical burns with over-the-counter muscle and joint products containing menthol, methyl salicylate or capsaicin. It identified 43 cases; most of the second- and third-degree burns involved products with more than 3% menthol and 10% methyl salicylate, and many occurred after a single application. FDA advised against tight bandaging, local heat and use on damaged skin (FDA, 2012 (archived copy); the original page has since been removed).

Absorption through the skin is the underlying mechanism worth understanding. About 10-20% of topical methyl salicylate is absorbed through intact skin within 10 hours (Hack, ACEP Now, 2025). In 12 volunteers using a 12.5% ointment twice daily for four days, urinary recovery rose from 15.5% of the applied dose on day 1 to about 22% on days 2-4, and the authors concluded that absorption "may increase with multiple applications" (Morra et al., 1996). Exercise in 40 C heat raised absorption more than threefold in six volunteers (Danon et al., 1986), and occlusion plus diseased skin was blamed in a case of salicylism after a herbal psoriasis cream (Bell and Duggin, 2002).

A 2017 review of topical salicylate poisoning also cites the death of a 17-year-old runner after excessive self-application of a topical methyl salicylate muscle product. The review's authors cite that case to a news item, and we have not read the underlying report (Anderson et al., 2017). For people on warfarin, the interaction reports are summarized on our page about aspirin sensitivity and blood thinners.

A note on "cooling" and "warming"

People often judge these products by sensation, so one study is worth knowing. In human skin tests, methyl salicylate "enhances the perception of warming but does not affect the perception of cooling," and the dominant sensation was burning (Green and Flammer, 1989). A warm or tingling feeling tells you the skin is being stimulated; it is not evidence that anything else has happened.

If you are asking because something hurts

Muscle and joint pain is a question for a pharmacist or physician, who can ask about the cause, your medications and your skin. Do not use a craft essential oil as a stand-in for a labeled product. If you already own a drug-labeled rub, its label requirements (external use only, avoid eyes, no wounds or damaged skin, no tight bandaging) are the minimum, and FDA's 2012 advice against adding heat applies to it. For the wider risk picture on this oil, start with the safety guide and the methyl salicylate explainer.

This is a sourced explainer by the shop, not individual medical advice, and no clinician has reviewed it. Ask a pharmacist or physician before using any methyl salicylate product, especially if you take anticoagulants.

Birch Essential Oil bottle

Birch Essential Oil

Birch Essential Oil from our own shop, in sizes from 1 oz to bulk.

From $15.99

Shop Now →

Sources & Further Reading